of a bDMARD or tsDMARD for patients with a serious infection within the previous 12 months who have moderate-to-high disease activity despite csDMARD monotherapy This conditional recommendation is made based on observational data suggesting a lower risk of infection associated with combination csDMARDs (dual or triple therapy) compared to bDMARDs or tsDMARDs Addition of/switching to DMARDs is conditionally recommended over initiation/dose escalation of glucocorticoids for patients with a